Vertex Pharmaceuticals annual cash and equivalents
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Vertex Pharmaceuticals Cash & Equivalents Growth & History (VRTX)
Vertex Pharmaceuticals's cash and equivalents was $5.08B for fiscal 2025.
View full Vertex Pharmaceuticals company overviewVertex Pharmaceuticals annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.08B | $515.2M | +11.27% |
| 2024 | 2024-12-31 | $4.57B | −$5.80B | −55.93% |
| 2023 | 2023-12-31 | $10.37B | −$134.9M | −1.28% |
| 2022 | 2022-12-31 | $10.50B | $3.71B | +54.58% |
| 2021 | 2021-12-31 | $6.79B | $806.8M | +13.47% |
| 2020 | 2020-12-31 | $5.99B | $2.88B | +92.59% |
| 2019 | 2019-12-31 | $3.11B | $459.2M | +17.33% |
| 2018 | 2018-12-31 | $2.65B | $984.7M | +59.13% |
| 2017 | 2017-12-31 | $1.67B | $481.5M | +40.67% |
| 2016 | 2016-12-31 | $1.18B | $469.2M | +65.64% |
| 2015 | 2015-12-31 | $714.8M | $89.5M | +14.32% |
| 2014 | 2014-12-31 | $625.3M | $56.0M | +9.83% |
| 2013 | 2013-12-31 | $569.3M | $79.9M | +16.32% |
| 2012 | 2012-12-31 | $489.4M | $14.1M | +2.96% |
| 2011 | 2011-12-31 | $475.3M | $232.1M | +95.45% |
| 2010 | 2010-12-31 | $243.2M | −$203.5M | −45.55% |
| 2009 | 2009-12-31 | $446.7M | $57.5M | +14.79% |
| 2008 | 2008-12-31 | $389.1M | — | — |
Vertex Pharmaceuticals quarterly cash and equivalents
Q4.08
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.14B | $1.17B | +23.56% |
| Q1 2026 | 2026-03-31 | $5.49B | $818.2M | +17.50% |
| Q4 2025 | 2025-12-31 | $5.08B | $515.2M | +11.27% |
| Q3 2025 | 2025-09-30 | $4.94B | −$299.6M | −5.72% |
| Q2 2025 | 2025-06-30 | $4.97B | $392.1M | +8.56% |
| Q1 2025 | 2025-03-31 | $4.67B | −$4.48B | −48.96% |
| Q4 2024 | 2024-12-31 | $4.57B | −$5.80B | −55.93% |
| Q3 2024 | 2024-09-30 | $5.24B | −$5.87B | −52.84% |
| Q2 2024 | 2024-06-30 | $4.58B | −$5.57B | −54.88% |
| Q1 2024 | 2024-03-31 | $9.16B | −$131.9M | −1.42% |
| Q4 2023 | 2023-12-31 | $10.37B | −$134.9M | −1.28% |
| Q3 2023 | 2023-09-30 | $11.11B | $1.94B | +21.14% |
| Q2 2023 | 2023-06-30 | $10.15B | $1.45B | +16.65% |
| Q1 2023 | 2023-03-31 | $9.29B | $1.69B | +22.23% |
| Q4 2022 | 2022-12-31 | $10.50B | $3.71B | +54.58% |
| Q3 2022 | 2022-09-30 | $9.17B | $2.90B | +46.14% |
| Q2 2022 | 2022-06-30 | $8.70B | $2.64B | +43.51% |
| Q1 2022 | 2022-03-31 | $7.60B | $1.30B | +20.55% |
| Q4 2021 | 2021-12-31 | $6.79B | $806.8M | +13.47% |
| Q3 2021 | 2021-09-30 | $6.28B | $917.6M | +17.13% |
| Q2 2021 | 2021-06-30 | $6.06B | $1.23B | +25.51% |
| Q1 2021 | 2021-03-31 | $6.30B | $2.71B | +75.44% |
| Q4 2020 | 2020-12-31 | $5.99B | $2.88B | +92.59% |
| Q3 2020 | 2020-09-30 | $5.36B | $1.96B | +57.69% |
| Q2 2020 | 2020-06-30 | $4.83B | $1.54B | +46.64% |
| Q1 2020 | 2020-03-31 | $3.59B | $699.5M | +24.17% |
| Q4 2019 | 2019-12-31 | $3.11B | $459.2M | +17.33% |
| Q3 2019 | 2019-09-30 | $3.40B | $919.6M | +37.11% |
| Q2 2019 | 2019-06-30 | $3.29B | $1.15B | +53.57% |
| Q1 2019 | 2019-03-31 | $2.89B | $898.0M | +44.99% |
| Q4 2018 | 2018-12-31 | $2.65B | $984.7M | +59.13% |
| Q3 2018 | 2018-09-30 | $2.48B | $1.09B | +78.94% |
| Q2 2018 | 2018-06-30 | $2.15B | $922.2M | +75.40% |
| Q1 2018 | 2018-03-31 | $2.00B | $992.2M | +98.86% |
| Q4 2017 | 2017-12-31 | $1.67B | $481.5M | +40.67% |
| Q3 2017 | 2017-09-30 | $1.38B | $665.3M | +92.44% |
| Q2 2017 | 2017-06-30 | $1.22B | $617.3M | +101.88% |
| Q1 2017 | 2017-03-31 | $1.00B | $399.4M | +66.10% |
| Q4 2016 | 2016-12-31 | $1.18B | $469.2M | +65.64% |
| Q3 2016 | 2016-09-30 | $719.7M | −$36.6M | −4.83% |
| Q2 2016 | 2016-06-30 | $605.9M | −$264.7M | −30.40% |
| Q1 2016 | 2016-03-31 | $604.2M | −$60.6M | −9.12% |
| Q4 2015 | 2015-12-31 | $714.8M | $89.5M | +14.32% |
| Q3 2015 | 2015-09-30 | $756.3M | $37.7M | +5.24% |
| Q2 2015 | 2015-06-30 | $870.5M | $450.0M | +107.00% |
| Q1 2015 | 2015-03-31 | $664.9M | $240.8M | +56.79% |
| Q4 2014 | 2014-12-31 | $625.3M | $56.0M | +9.83% |
| Q3 2014 | 2014-09-30 | $718.6M | $135.4M | +23.21% |
| Q2 2014 | 2014-06-30 | $420.6M | −$110.7M | −20.84% |
| Q1 2014 | 2014-03-31 | $424.0M | $44.9M | +11.86% |
| Q4 2013 | 2013-12-31 | $569.3M | $79.9M | +16.32% |
| Q3 2013 | 2013-09-30 | $583.2M | $146.3M | +33.49% |
| Q2 2013 | 2013-06-30 | $531.2M | $77.2M | +17.00% |
| Q1 2013 | 2013-03-31 | $379.1M | −$75.0M | −16.51% |
| Q4 2012 | 2012-12-31 | $489.4M | $14.1M | +2.96% |
| Q3 2012 | 2012-09-30 | $436.9M | −$105.7M | −19.47% |
| Q2 2012 | 2012-06-30 | $454.1M | −$4.1M | −0.90% |
| Q1 2012 | 2012-03-31 | $454.1M | $7.5M | +1.69% |
| Q4 2011 | 2011-12-31 | $475.3M | $232.1M | +95.45% |
| Q3 2011 | 2011-09-30 | $542.5M | −$27.4M | −4.80% |
| Q2 2011 | 2011-06-30 | $458.2M | $120.6M | +35.72% |
| Q1 2011 | 2011-03-31 | $446.5M | $50.0M | +12.61% |
| Q4 2010 | 2010-12-31 | $243.2M | −$203.5M | −45.55% |
| Q3 2010 | 2010-09-30 | $569.9M | — | — |
| Q2 2010 | 2010-06-30 | $337.6M | — | — |
| Q1 2010 | 2010-03-31 | $396.5M | — | — |
| Q4 2009 | 2009-12-31 | $446.7M | $57.5M | +14.79% |
| Q4 2008 | 2008-12-31 | $389.1M | — | — |
Vertex Pharmaceuticals cash and equivalents trends
Over the last five fiscal years, Vertex Pharmaceuticals's cash and equivalents decreased from $5.99B to $5.08B, a change of −$903.4M. The latest reported quarter, Q2 2026, shows $6.14B.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vertex Pharmaceuticals source filings ↗